MGP Database

New search | Record Overview | Ontology/Pathway Information | Domain Information | UniProt Annotations | Related Proteins
MGP000978

UniProt Annotations

Entry Information
Gene Nameerb-b2 receptor tyrosine kinase 2
Protein EntryERBB2_HUMAN
UniProt IDP04626
SpeciesHuman
Comments
Comment typeDescription
Alternative ProductsEvent=Alternative splicing, Alternative initiation; Named isoforms=6; Name=1; Synonyms=ERBB2, HER2; IsoId=P04626-1; Sequence=Displayed; Name=2; Synonyms=CTF-611; IsoId=P04626-2; Sequence=VSP_039249; Note=Produced by alternative initiation at Met-611 of isoform 1.; Name=3; Synonyms=CTF-687; IsoId=P04626-3; Sequence=VSP_039250; Note=Produced by alternative initiation at Met-687 of isoform 1.; Name=4; IsoId=P04626-4; Sequence=VSP_039248; Note=Produced by alternative splicing of isoform 1.; Name=5; IsoId=P04626-5; Sequence=VSP_054787; Note=No experimental confirmation available. Gene prediction based on partial mRNA and EST data.; Name=6; Synonyms=B; IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904;
Catalytic ActivityATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE- ProRule:PRU10028, ECO:0000269|PubMed:21454582}.
DiseaseGastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. Note=The gene represented in this entry is involved in disease pathogenesis.
DiseaseGlioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Note=The gene represented in this entry is involved in disease pathogenesis.
DiseaseHereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=The gene represented in this entry is involved in disease pathogenesis.
DiseaseLung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The gene represented in this entry is involved in disease pathogenesis.
DiseaseNote=Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2.
DiseaseOvarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
Enzyme RegulationActivated by dimerization. Not activated by EGF, TGF-alpha and amphiregulin. Interaction with PTK6 increases its intrinsic kinase activity. {ECO:0000269|PubMed:18719096, ECO:0000269|PubMed:21454582}.
FunctionIn the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
FunctionProtein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
InteractionSelf; NbExp=9; IntAct=EBI-641062, EBI-641062; P00519:ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543; P42684:ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694; P60709:ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944; Q92625:ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612; O00213:APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694; O75815:BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336; Q16543:CDC37; NbExp=3; IntAct=EBI-641062, EBI-295634; Q9NSE2:CISH; NbExp=4; IntAct=EBI-641062, EBI-617866; Q7Z7G1:CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194; P46109:CRKL; NbExp=2; IntAct=EBI-641062, EBI-910; Q99704:DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360; Q8TEW6:DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542; Q15075:EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113; P98172:EFNB1; NbExp=11; IntAct=EBI-641062, EBI-538287; P00533:EGFR; NbExp=20; IntAct=EBI-641062, EBI-297353; P21860:ERBB3; NbExp=24; IntAct=EBI-641062, EBI-720706; Q15303:ERBB4; NbExp=2; IntAct=EBI-641062, EBI-80371; P09769:FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732; P06241:FYN; NbExp=2; IntAct=EBI-641062, EBI-515315; O75791:GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418; P62993:GRB2; NbExp=4; IntAct=EBI-641062, EBI-401755; Q14451:GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191; O75367:H2AFY; NbExp=6; IntAct=EBI-641062, EBI-2868511; O75367-3:H2AFY; NbExp=3; IntAct=EBI-641062, EBI-6250866; P07900:HSP90AA1; NbExp=4; IntAct=EBI-641062, EBI-296047; P08238:HSP90AB1; NbExp=3; IntAct=EBI-641062, EBI-352572; P46940:IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509; P35568:IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592; Q08881:ITK; NbExp=2; IntAct=EBI-641062, EBI-968552; P23458:JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438; Q14974:KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758; Q9UQF2:MAPK8IP1; NbExp=3; IntAct=EBI-641062, EBI-78404; Q13387:MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813; P42679:MATK; NbExp=2; IntAct=EBI-641062, EBI-751664; Q9Y316:MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564; O43639:NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635; Q02297-7:NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927; O00750:PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107; P27986:PIK3R1; NbExp=11; IntAct=EBI-641062, EBI-79464; O00459:PIK3R2; NbExp=6; IntAct=EBI-641062, EBI-346930; Q92569:PIK3R3; NbExp=9; IntAct=EBI-641062, EBI-79893; P19174:PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387; P16885:PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403; O95602:POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472; Q05397:PTK2; NbExp=2; IntAct=EBI-641062, EBI-702142; Q13882:PTK6; NbExp=2; IntAct=EBI-641062, EBI-1383632; Q06124:PTPN11; NbExp=2; IntAct=EBI-641062, EBI-297779; Q05209:PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035; P23467:PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766; P08575:PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341; Q12913:PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500; Q15262:PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052; Q16827:PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739; P49792:RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138; P20936:RASA1; NbExp=7; IntAct=EBI-641062, EBI-1026476; O95980:RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742; Q9NP31:SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630; P29353:SHC1; NbExp=9; IntAct=EBI-641062, EBI-78835; P98077:SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023; Q92529:SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084; Q9H6Q3:SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854; O15524:SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198; P12931:SRC; NbExp=11; IntAct=EBI-641062, EBI-621482; P42224:STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697; P40763:STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675; Q7KZ85:SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547; P43405:SYK; NbExp=7; IntAct=EBI-641062, EBI-78302; Q63HR2:TENC1; NbExp=4; IntAct=EBI-641062, EBI-949753; Q9Y490:TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036; Q68CZ2:TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488; Q96D37:VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353; P52735:VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549; O14980:XPO1; NbExp=2; IntAct=EBI-641062, EBI-355867;
PolymorphismThere are four alleles due to the variations in positions 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val-654/Val-655) has a frequency of 0.012.
PtmAutophosphorylated. Ligand-binding increases phosphorylation on tyrosine residues. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Signaling via SEMA4C promotes phosphorylation at Tyr-1248. {ECO:0000269|PubMed:17081983, ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:18691976, ECO:0000269|PubMed:20068231, ECO:0000269|PubMed:21406692}.
SimilarityBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- ProRule:PRU00159}.
SimilarityContains 1 protein kinase domain. {ECO:0000255|PROSITE-ProRule:PRU00159}.
Subcellular LocationIsoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm, perinuclear region. Nucleus. Note=Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1.
Subcellular LocationIsoform 2: Cytoplasm. Nucleus.
Subcellular LocationIsoform 3: Cytoplasm. Nucleus.
SubunitHomodimer. Heterodimer with EGFR, ERBB3 and ERBB4. Part of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196. Interacts with PRKCABP and PLXNB1. Interacts (when phosphorylated on Tyr-1248) with MEMO1. Interacts with MUC1; the interaction is enhanced by heregulin (HRG). Interacts (when phosphorylated on Tyr-1139) with GRB7 (via SH2 domain). Interacts (when phosphorylated on Tyr-1248) with ERBB2IP. Interacts with KPNB1, RANBP2, EEA1, CRM1, CLTC, PTK6, RPA94 and ACTB. Interacts with SRC and MYOC (By similarity). {ECO:0000250}.
Tissue SpecificityExpressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth. {ECO:0000269|PubMed:15380516}.
Web ResourceName=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/ERBB2ID162ch17q11.html";
Web ResourceName=NIEHS-SNPs; URL="http://egp.gs.washington.edu/data/erbb2/";
Web ResourceName=Wikipedia; Note=ERBB2 entry; URL="http://en.wikipedia.org/wiki/ERBB2";
  logo